Soluble RANKL in crevicular fluid of dental implants: A pilot study

Clinical Implant Dentistry and Related Research

Volumn 8, Issue 3, 2006, Pages 135-141

  Monov, Gabriel ^a   Strbac, Georg D ^a   Baron, Monika ^a   Kandler, Barbara ^a   Watzek, Georg ^a,b   Gruber, Reinhard ^a,b,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c Department of Oral Surgery ^*  (Austria)

Author keywords

Inflammation; Osseointegration; Osteoclast; Peri implantitis; RANKL

Indexed keywords

BIOLOGICAL MARKER; CARRIER PROTEIN; LIGAND; MEMBRANE PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR;

ADULT; AGED; ARTICLE; CHEMISTRY; CLASSIFICATION; FEMALE; GINGIVA BLEEDING; GINGIVITIS; HUMAN; MALE; MIDDLE AGED; OSTEOCLAST; OSTEOLYSIS; PATHOLOGY; PERIODONTICS; PERIODONTITIS; PILOT STUDY; PROGNOSIS; SOLUBILITY; TOOTH IMPLANTATION; TOOTH PLAQUE;

ADULT; AGED; AGED, 80 AND OVER; ALVEOLAR BONE LOSS; BIOLOGICAL MARKERS; CARRIER PROTEINS; DENTAL IMPLANTS; DENTAL PLAQUE INDEX; FEMALE; GINGIVAL CREVICULAR FLUID; GINGIVAL HEMORRHAGE; HUMANS; LIGANDS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; OSTEOCLASTS; PERIODONTAL INDEX; PERIODONTAL POCKET; PERIODONTITIS; PILOT PROJECTS; PROGNOSIS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, TUMOR NECROSIS FACTOR; SOLUBILITY; TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PEPTIDES AND PROTEINS;

EID: 33748928452     PISSN: 15230899     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1708-8208.2006.00012.x     Document Type: Article

References (35)

1. Albrektsson TO, Johansson CB, Sennerby L. Biological aspects of implant dentistry: osseointegration. Periodontol 2000 1994; 4:58-73.
2. Davies JE. Understanding peri-implant endosseous healing. J Dent Educ 2003; 67:932-949.
3. Pjetursson BE, Tan K, Lang NP, Bragger U, Egger M, Zwahlen M. A systematic review of the survival and complication rates of fixed partial dentures (FPDs) after an observation period of at least 5 years. Clin Oral Implants Res 2004; 15:625-642.
4. Mombelli A, Lang NP. The diagnosis and treatment of peri-implantitis. Periodontol 2000 1998; 17:63-76.
5. Hultin M, Gustafsson A, Hallstrom H, Johansson LA, Ekfeldt A, Klinge B. Microbiological findings and host response in patients with peri-implantitis. Clin Oral Implants Res 2002; 13:349-358.
6. Bullon P, Fioroni M, Goteri G, Rubini C, Battino M. Immunohistochemical analysis of soft tissues in implants with healthy and peri-implantitis condition, and aggressive periodontitis. Clin Oral Implants Res 2004; 15:553-559.
7. Gualini F, Berglundh T. Immunohistochemical characteristics of inflammatory lesions at implants. J Clin Periodontol 2003; 30:14-18.
8. Roos-Jansaker AM, Renvert S, Egelberg J. Treatment of peri-implant infections: a literature review. J Clin Periodontol 2003; 30:467-485.
9. Griffiths GS. Formation, collection and significance of gingival crevice fluid. Periodontol 2000 2003; 31:32-42.
10. Murata M, Tatsumi J, Kato Y, et al. Osteocalcin, deoxypyridinoline and interleukin-1beta in peri-implant crevicular fluid of patients with peri-implantitis. Clin Oral Implants Res 2002; 13:637-643.
11. Ataoglu H, Alptekin NO, Haliloglu S, et al. Interleukin-1 beta, tumor necrosis factor-alpha levels and neutrophil elastase activity in peri-implant crevicular fluid. Clin Oral Implants Res 2002; 13:470-476.
12. Kivela-Rajamaki M, Maisi P, Srinivas R, et al. Levels and molecular forms of MMP-7 (matrilysin-1) and MMP-8 (collagenase-2) in diseased human peri-implant sulcular fluid. J Periodontal Res 2003; 38:583-590.
13. Kivela-Rajamaki MJ, Teronen OP, Maisi P, et al. Laminin-5 gamma2-chain and collagenase-2 (MMP-8) in human peri-implant sulcular fluid. Clin Oral Implants Res 2003; 14:158-165.
14. Ma J, Kitti U, Hanemaaijer R, et al. Gelatinase B is associated with peri-implant bone loss. Clin Oral Implants Res 2003; 14:709-713.
15. Redlich K, Hayer S, Ricci R, et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002; 110:1419-1427.
16. Pettit AR, Ji H, von Stechow D, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001; 159:1689-1699.
17. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003; 4:638-649.
18. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423:337-342.
19. Lerner UH. New molecules in the tumor necrosis factor ligand and receptor superfamiles with importance for physiological and pathological bone resorption. Crit Rev Oral Biol Med 2004; 31:475-482.
20. Lum L, Wong BR, Josien R, et al. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 1999; 274:13613-13618.
21. Crotti TN, Ahern MJ, Lange K, et al. Variability of RANKL and osteoprotegerin staining in synovial tissue from patients with active rheumatoid arthritis: quantification using color video image analysis. J Rheumatol 2003; 30:2319-2324.
22. Horiki M, Nakase T, Myoui A, et al. Localization of RANKL in osteolytic tissue around a loosened joint prosthesis. J Bone Miner Metab 2004; 22:346-351.
23. Mandelin J, Li TF, Liljestrom M, et al. Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement. J Bone Joint Surg Br 2003; 85:1196-1201.
24. Crotti TN, Smith MD, Findlay DM, et al. Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. Biomaterials 2004; 25:565-573.
25. Crotti T, Smith MD, Hirsch R, et al. Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J Periodontal Res 2003; 38:380-387.
26. Mogi M, Otogoto J, Ota N, Togari A. Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis. J Dent Res 2004; 83:166-169.
27. Silness J, Loee H. Periodontal disease in pregnancy. II. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand 1964; 22:121-135.
28. Mombelli A, van Oosten MA, Schurch E, Jr., Land, NP. The microbiota associated with successful or failing osseointegrated titanium implants. Oral Microbiol Immunol 1987; 2:145-151.
29. Hawa G, Brinskelle-Schmal N, Glatz K, Maitzen S, Woloszczuk W. Immunoassay for soluble RANKL (receptor activator of NF-kappaB ligand) in serum. Clin Lab 2003; 49:461-463.
30. Ziolkowska M, Kurowska M, Radzikowska A, et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 2002; 46:1744-1753.
31. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106:1481-1488.
32. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005; 115:282-290.
33. Roggia C, Gao Y, Cenci S, et al. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci U S A 2001; 98:13960-13965.
34. Weaver AL. The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2004; 43(Suppl 3):iii17-iii23.
35. Hofbauer LC, Lacey DL, Dunstan CR, Speisberg TC, Riggs BL, Khosla S. Interleukin-lbeta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999; 25:255-259.